Jeffries Oliver-Li's practice focuses on corporate and securities law matters. He represents companies in public offerings, venture capital financings and mergers and acquisitions. Mr. Oliver-Li also advises companies with respect to securities law compliance and disclosures and general corporate matters.

Mr. Oliver-Li's public company clients include Casa Systems, Catabasis Pharmaceuticals, Editas Medicine, EverQuote and PerkinElmer.

Mr. Oliver-Li's transactional practice has included representation of:

  • Casella Waste Systems, Inc. in its tender offer for and redemption of $195 million of senior subordinated notes;
  • Catabasis Pharmaceuticals, Inc. in its $69 million initial public offering;
  • Constellation Pharmaceuticals, Inc. in its $55 million mezzanine financing;
  • CoreStreet, Ltd. in its acquisition by ActivIdentity Corporation for $19 million;
  • Editas Medicine, Inc. in its $109 million initial public offering;
  • Netezza Corporation in its acquisition by IBM for $1.9 billion;
  • Sonus Networks, Inc. in its acquisition of Network Equipment Technologies, Inc. for $42 million;
  • Tangoe, Inc. in its $100 million initial public offering and its $170 million follow-on offering; and
  • Tetraphase Pharmaceuticals, Inc. in its $80 million initial public offering.

While in law school, Mr. Oliver-Li held a summer associate position with WilmerHale, working primarily in corporate law and litigation.

Insights & News

Credentials

  • Education

    • JD, Harvard Law School, 2006

      cum laude Harvard Journal of Law & Technology
    • AB, History of Art & Architecture, Harvard College, 2003

      summa cum laude Phi Beta Kappa, Thomas Temple Hoopes Prize
  • Admissions

    • Massachusetts

    • Colorado

Credentials

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.